Multicenter study of the impact of Urolift® implantation in patients undergoing medical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

• Tác giả: C Barrera Rodríguez, A Budía Alba, J Campá Bortoló, J Extramiana Cameno, M Fernández Arjona, V Gimeno Argente, C González Enguita, L M Herranz Fernández, E López Alcina, L López Martín, A Navarro Beltrán, J Ortiz Salvador, J M Oscá García, M Perán Teruel, I Povo Martín, J J Salgado Plonski, Y Salvador Pallás Costa, B Sinues Ojas, P Suárez Sal
• Ngôn ngữ: eng
• Ký hiệu phân loại: 627.12 Rivers and streams
• Thông tin xuất bản: Spain : Actas urologicas espanolas , 2025
• Bộ sưu tập: NCBI
• ID: 196200

Tóm tắt

 INTRODUCTION AND OBJECTIVES: UroLift® is a minimally invasive treatment for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The primary objective was to evaluate the impact of UroLift® system treatment on quality of life. Secondary objectives assessed the impact on urinary symptoms and sexual function. PATIENTS AND METHODS: Patients at 7 Spanish hospitals undergoing pharmacological treatment were offered the choice to continue this treatment or accept surgical intervention. The primary outcome, impact on quality of life, was assessed using the EuroQol-5D-5L questionnaire. Secondary outcomes, including impact on symptoms, erectile function, and ejaculatory function, were evaluated using the IPSS, SHIM-5, and MSHQ-EjD-SF questionnaires, respectively. Outcomes were compared between groups. RESULTS: 91 patients chose UroLift® and 45 continued with pharmacotherapy. At 6 months, a positive impact on quality of life was estimated with UroLift® (0.046
  SD: 0.02
  p = 0.067), being significant in subgroups of patients aged >
 65 years (diff.: 0.034), PSA >
  2.2 (diff.: 0.108), diabetes mellitus (diff.: 0.023), hypertension (diff.: 0.011) or hypercholesterolemia (diff.: 0.016). The impact on symptomatology was superior with UroLift® (-10.07
  SD: 1.65
  p <
  0.001), being significant in subgroups aged >
 65 (diff.: 1.37), prostate >
 40 cc (diff.: 0.74), PSA >
  2.2 (diff.: 2.63), and diabetes mellitus (diff.: 1.66), hypertension (diff.: 1.23). Erectile function was not affected (-0.33
  SD: 1.99
  p = 0.868) while ejaculatory function showed a favorable impact (2.98
  SD: 1.26
  p = 0.019). CONCLUSIONS: Minimally invasive Urolift® system treatment is associated with a positive impact on quality of life and urinary symptoms without adversely affecting sexual function.